Ascendis Pharma A/S $ASND Shares Sold by Massachusetts Financial Services Co. MA

Massachusetts Financial Services Co. MA lowered its stake in Ascendis Pharma A/S (NASDAQ:ASND) by 1.0% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 1,882,781 shares of the biotechnology company’s stock after selling 19,062 shares during the quarter. Massachusetts Financial Services Co. MA owned about 3.05% of Ascendis Pharma A/S worth $374,316,000 at the end of the most recent quarter.

Several other hedge funds also recently bought and sold shares of ASND. Compagnie Lombard Odier SCmA purchased a new stake in shares of Ascendis Pharma A/S in the 2nd quarter valued at approximately $39,000. First Horizon Advisors Inc. acquired a new stake in Ascendis Pharma A/S in the 2nd quarter valued at approximately $41,000. Hantz Financial Services Inc. raised its position in Ascendis Pharma A/S by 291.1% in the second quarter. Hantz Financial Services Inc. now owns 352 shares of the biotechnology company’s stock valued at $61,000 after purchasing an additional 262 shares during the period. Farther Finance Advisors LLC raised its position in Ascendis Pharma A/S by 115.3% in the third quarter. Farther Finance Advisors LLC now owns 478 shares of the biotechnology company’s stock valued at $95,000 after purchasing an additional 256 shares during the period. Finally, Toth Financial Advisory Corp lifted its stake in Ascendis Pharma A/S by 33.7% during the third quarter. Toth Financial Advisory Corp now owns 595 shares of the biotechnology company’s stock worth $118,000 after purchasing an additional 150 shares in the last quarter.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on the company. Stifel Nicolaus lifted their price objective on Ascendis Pharma A/S from $254.00 to $256.00 and gave the company a “buy” rating in a research note on Thursday, December 11th. Wedbush reaffirmed an “outperform” rating and issued a $220.00 target price on shares of Ascendis Pharma A/S in a research report on Tuesday, November 18th. Cantor Fitzgerald reissued an “overweight” rating on shares of Ascendis Pharma A/S in a research report on Wednesday, November 26th. Wells Fargo & Company raised their price objective on shares of Ascendis Pharma A/S from $297.00 to $322.00 and gave the company an “overweight” rating in a research note on Friday, January 9th. Finally, Cowen reaffirmed a “buy” rating on shares of Ascendis Pharma A/S in a research note on Wednesday, January 7th. Two equities research analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Buy” and a consensus price target of $262.69.

Ascendis Pharma A/S Stock Performance

Shares of Ascendis Pharma A/S stock opened at $205.83 on Monday. The business has a 50-day simple moving average of $208.70 and a 200-day simple moving average of $198.15. Ascendis Pharma A/S has a one year low of $118.03 and a one year high of $229.94. The company has a market cap of $12.76 billion, a PE ratio of -46.36, a P/E/G ratio of 1.09 and a beta of 0.46.

Ascendis Pharma A/S (NASDAQ:ASND) last issued its earnings results on Thursday, November 13th. The biotechnology company reported ($1.17) earnings per share for the quarter, missing the consensus estimate of ($0.41) by ($0.76). The company had revenue of $250.71 million for the quarter, compared to analysts’ expectations of $246.91 million. On average, sell-side analysts predict that Ascendis Pharma A/S will post -4.34 earnings per share for the current fiscal year.

About Ascendis Pharma A/S

Ascendis Pharma A/S is a Denmark‐based biopharmaceutical company focused on developing innovative therapies for rare endocrine diseases. Founded in 2015 and headquartered in Hellerup, the company leverages its proprietary TransCon drug delivery platform to create long‐acting prodrugs designed to improve safety, efficacy and patient convenience. Ascendis Pharma maintains research and development operations in Europe and the United States, with clinical studies spanning North America, Europe and Asia.

The company’s lead product, lonapegsomatropin (Skytrofa®), is a once‐weekly growth hormone therapy approved by the U.S.